{
    "ticker": "PHCFF",
    "name": "PharmaCyte Biotech, Inc.",
    "description": "PharmaCyte Biotech, Inc. is a biotechnology company focused on developing and commercializing innovative treatments for cancer and diabetes. Established in 1990 and headquartered in Los Angeles, California, PharmaCyte is best known for its proprietary technology platform, which utilizes live cell encapsulation to deliver therapeutic agents directly to tumors. This unique approach aims to enhance the efficacy and safety of treatments by targeting cancer cells while minimizing damage to surrounding healthy tissue. The company\u2019s lead product candidate, known as CypCaps, is being investigated as a potential treatment for pancreatic cancer, a disease with a high unmet medical need. In addition to its cancer research, PharmaCyte is also exploring therapies for diabetes via its encapsulated live cell technology. The company collaborates with various research institutions and clinical partners to advance its clinical trials and scientific understanding of its treatment methodologies. PharmaCyte's mission is to provide groundbreaking therapies that improve the quality of life for patients battling serious diseases. As the company continues to develop its pipeline, it strives to contribute significantly to the fields of oncology and regenerative medicine, aiming to change the landscape of treatment options available to patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Los Angeles, California, USA",
    "founded": "1990",
    "website": "https://www.pharmacytebiotech.com",
    "ceo": "Kenneth L. D. K. E. A. K. O. K. Hamasaki",
    "social_media": {
        "twitter": "https://twitter.com/PharmaCyte",
        "linkedin": "https://www.linkedin.com/company/pharmacyte-biotech-inc/"
    },
    "investor_relations": "https://www.pharmacytebiotech.com/investor-relations",
    "key_executives": [
        {
            "name": "Kenneth L. D. K. E. A. K. O. K. Hamasaki",
            "position": "CEO"
        },
        {
            "name": "Michael A. McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Treatments",
            "products": [
                "CypCaps"
            ]
        },
        {
            "category": "Diabetes Treatments",
            "products": []
        }
    ],
    "seo": {
        "meta_title": "PharmaCyte Biotech, Inc. | Innovative Cancer and Diabetes Treatments",
        "meta_description": "Explore PharmaCyte Biotech, Inc., a biotechnology company dedicated to developing innovative therapies for cancer and diabetes through its proprietary cell encapsulation technology.",
        "keywords": [
            "PharmaCyte",
            "Biotechnology",
            "Cancer Treatment",
            "Diabetes Treatment",
            "CypCaps"
        ]
    },
    "faq": [
        {
            "question": "What is PharmaCyte Biotech known for?",
            "answer": "PharmaCyte Biotech is known for its innovative cancer and diabetes treatments utilizing live cell encapsulation technology."
        },
        {
            "question": "Who is the CEO of PharmaCyte Biotech?",
            "answer": "Kenneth L. D. K. E. A. K. O. K. Hamasaki is the CEO of PharmaCyte Biotech, Inc."
        },
        {
            "question": "Where is PharmaCyte Biotech headquartered?",
            "answer": "PharmaCyte Biotech is headquartered in Los Angeles, California, USA."
        },
        {
            "question": "What is CypCaps?",
            "answer": "CypCaps is PharmaCyte's lead product candidate, being developed as a potential treatment for pancreatic cancer."
        },
        {
            "question": "When was PharmaCyte Biotech founded?",
            "answer": "PharmaCyte Biotech was founded in 1990."
        }
    ],
    "competitors": [
        "CLVS",
        "CRMD",
        "AXSM",
        "NTRA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BMY"
    ]
}